A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases
Artikel i vetenskaplig tidskrift, 2026
Cardiovascular diseases (CVD) remain a major global health challenge. Early markers of disease initiation and progression are urgently needed. We, and others, have previously shown changes in the gut microbiome in association with metabolic and CVD. Here, we demonstrate that gut microbiome-related changes can be detected in association with subclinical variations in heart and kidney function. Markers related to gut microbial metabolism of aromatic amino acids, phenylalanine and tyrosine, associate with circulating pro-atrial natriuretic peptide and estimated glomerular filtration rate in a metabolically healthy European population. Observational and genetic evidence further identify microbiome-related metabolites as mediators of this gut microbiome-kidney axis, with their baseline levels associating with incident CVD in an external Canadian population. Altogether, our work suggests that the gut microbiome interacts with the cardiorenal axis and participates in an interorgan crosstalk affecting host physiology and risk of CVD.
Författare
Kanta Chechi
Imperial College London
National Heart and Lung Institute
Rima Chakaroun
Universität Leipzig
Wallenberg Lab.
Antonis Myridakis
Imperial College London
Sofia K. Forslund
Deutsches Zentrum für Herz-Kreislauf-Forshung (DZHK)
Charité Universitätsmedizin Berlin
Max Delbrueck Centrum Fuer Molekulare Medizin
Sebastien Fromentin
Université Paris-Saclay
Trine Nielsen
Köpenhamns universitet
Sjællands Universitetshospital
Steno Diabetes Center
Novo Nordisk Fonden
Judith Aron-Wisneswky
Université Pierre et Marie Curie (UPMC)
Assistance publique – Hôpitaux de Paris (AP-HP)
Eugeni Belda
Université Pierre et Marie Curie (UPMC)
Edi Prifti
Université Pierre et Marie Curie (UPMC)
Pierre Bel-Lassen
Assistance publique – Hôpitaux de Paris (AP-HP)
Université Pierre et Marie Curie (UPMC)
Gwen Falony
KU Leuven
Wageningen University and Research
University Medical Center Mainz
Flanders Interuniversity Institute for Biotechnology
Sara Vieira-Silva
Universite catholique de Louvain
University Medical Center Mainz
Flanders Interuniversity Institute for Biotechnology
KU Leuven
J. Chilloux
Imperial College London
Kazuhiro Sonomura
Shimadzu Corporation
L. Hoyles
Imperial College London
Nottingham Trent University
Laura Martinez-Gili
Imperial College London
Francesco Pallotti
Imperial College London
Università degli Studi di Enna “Kore”
Petros Andrikopoulos
Imperial College London
Francesc Puig-Castellvi
Lille University Hospital
Romina Pacheco Tapia
Lille University Hospital
Inés Castro-Dionicio
Lille University Hospital
Hugo Roume
Université Paris-Saclay
Nicolas Pons
Université Paris-Saclay
Emmanuelle Le Chatelier
Université Paris-Saclay
Benoit Quinquis
Université Paris-Saclay
Nathalie Galleron
Université Paris-Saclay
Magali Berland
Université Paris-Saclay
Michael Olanipekun
Imperial College London
Manyi Jia
Imperial College London
Angelos Manolias
Imperial College London
Bridget Holmes
Food and Agriculture Organization of the United Nations
Danone Research
Solia Adriouch
Université Pierre et Marie Curie (UPMC)
M. Bluher
Universität Leipzig
Luis P. Coelho
European Molecular Biology Laboratory
Kévin Da Silva
Université Paris-Saclay
Pilar Galan
Inserm Transfert
Boyang Ji
Chalmers, Life sciences, Systembiologi
BioInnovation Institute
Ana Luisa Neves
Imperial College London
Christine Rouault
Université Pierre et Marie Curie (UPMC)
Joe-Elie Salem
Assistance publique – Hôpitaux de Paris (AP-HP)
Valentina Tremaroli
Wallenberg Lab.
Tue H. Hansen
Novo Nordisk Fonden
Köpenhamns universitet
Sjællands Universitetshospital
Nadja B. Søndertoft
Novo Nordisk Fonden
Christian Lewinter
Novo Nordisk Fonden
Helle K. Pedersen
Novo Nordisk Fonden
Peter D. Mark
Rigshospitalet
Jens P. Goetze
Rigshospitalet
Lars Køber
Rigshospitalet
Köpenhamns universitet
H. Vestergaard
Steno Diabetes Center
Novo Nordisk Fonden
Torben Hansen
Syddansk Universitet
Novo Nordisk Fonden
Jean-Daniel Zucker
Université Pierre et Marie Curie (UPMC)
Taka Aki Sato
Shimadzu Corporation
Serge Hercberg
Inserm Transfert
Fredrik Bäckhed
Wallenberg Lab.
Sahlgrenska universitetssjukhuset
Ivica Letunic
Universität Heidelberg
Biobyte Solutions
Jean-Michel Oppert
Assistance publique – Hôpitaux de Paris (AP-HP)
Jens B Nielsen
BioInnovation Institute
Chalmers, Life sciences, Systembiologi
Jeroen Raes
KU Leuven
Flanders Interuniversity Institute for Biotechnology
Ioanna Tzoulaki
Imperial College London
Academy of Athens
Abbas Dehghan
Imperial College London
Verena Zuber
Imperial College London
Emmanuelle Bouzigon
Inserm Transfert
Mark Lathrop
McGill University
Parminder Raina
McMaster University
Philippe Froguel
Imperial College London
Lille University Hospital
Fumihiko Matsuda
Kyoto University
Florence Demenais
Inserm Transfert
Dominique Gauguier
Centre national de la recherche scientifique (CNRS)
Kyoto University
McGill University
M. Stumvoll
Universität Leipzig
Peer Bork
European Molecular Biology Laboratory
Max Delbrueck Centrum Fuer Molekulare Medizin
Universität Heidelberg
O. B. Pedersen
Novo Nordisk Fonden
Gentofte Hospital
Köpenhamns universitet
Stanislav Dusko Ehrlich
Université Paris-Saclay
University College London (UCL)
K. Clement
Université Pierre et Marie Curie (UPMC)
Assistance publique – Hôpitaux de Paris (AP-HP)
Marc-Emmanuel Dumas
McGill University
Lille University Hospital
Imperial College London
National Heart and Lung Institute
Nature Communications
2041-1723 (ISSN) 20411723 (eISSN)
Vol. 17 1Ämneskategorier (SSIF 2025)
Mikrobiologi inom det medicinska området
Kardiologi och kardiovaskulära sjukdomar
Endokrinologi och diabetes
DOI
10.1038/s41467-026-69405-0
PubMed
41786749